{"success":true,"data":{"pressRelease":{"id":"101914","rtpr_id":"nGNX6KDbcy","ticker":"ENLV","exchange":"NASDAQ","all_tickers":["ENLV","1BTG"],"title":"Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones","author":"Globe Newswire","published_at":"2026-07-29T12:00:00.473Z","article_body":"Webinar to cover the rationale and value creation potential of the recently\nannounced private placement, an update on Rain protocol milestones, and recent\nclinical progress for Allocetra™, including its new RMAT designation from\nthe FDA\n\nNes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:\nENLV, “Enlivex” or “the Company”), a quality longevity company powered\nby a prediction markets treasury, today announced that its management team\nwill host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time\nto provide investors with additional detail on the Company’s recently\nannounced private placement (the “Transaction”), the status and strategy\nof its RAIN treasury, and recent clinical progress for Allocetra™.\n\nWebinar Agenda\n\nCompany management will provide an update across three areas:\n\n●     Private Placement & Treasury Strategy: the rationale for the\nTransaction, the Company’s intended use of proceeds, and how the Transaction\nfits within the Company’s long-term treasury strategy built around the Rain\nprotocol\n\n●     Rain Protocol Update: current status of the Company’s treasury\nportfolio and a review of recent milestones and the growth roadmap provided by\nthe Rain Foundation\n\n●     Clinical Update – Allocetra™: progress of the ongoing Phase 2b\ntrial in age-related knee osteoarthritis, and the recently granted\nRegenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food\nand Drug Administration (FDA) for Allocetra™ in the treatment of symptomatic\nknee osteoarthritis in patients aged 64 and older\n\nWebinar Details\n\nDate/Time: Thursday, July 30, 2026, at 10:00 AM Eastern Time\n\nRegistration: https://www.redchip.com/webinar/ENLV/82414254076\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any securities.\n\n ABOUT ENLIVEX\n\nEnlivex is a quality longevity company powered by a prediction markets\ntreasury. The Company is advancing Allocetra™, an advanced clinical-stage\nimmunotherapy targeting inflammatory conditions associated with aging, with a\nprimary focus on age-related osteoarthritis. In addition to its clinical\nprograms, Enlivex operates a prediction markets treasury strategy built around\nthe Rain protocol, the leading decentralized prediction markets infrastructure\non Arbitrum. This dual strategy combines the development of quality longevity\ntherapeutics with exposure to the emerging prediction markets ecosystem.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\nmay be identified by words such as “expects,” “plans,” “projects,”\n“will,” “may,” “anticipates,” “believes,” “should,”\n“would,” “could,” “intends,” “estimates,” “suggests,”\n“target,” “has the potential to,” “goal,” and other words of\nsimilar meaning, including statements relating to the anticipated benefits and\ntiming of the completion of the proposed Transaction and related transactions\nand the intended use of proceeds from the Transaction; the anticipated\nbenefits of the Company’s digital asset treasury strategy; the assets to be\nheld by the Company; the expected future market, price, trading activity, and\nliquidity of the RAIN token; the impact of expanded exchange listings and\nincreased token liquidity on market participation and accessibility; the\npotential effects of digital asset liquidity on the liquidity of the\nCompany’s ordinary shares; macroeconomic, political, and regulatory\nconditions surrounding digital assets; the Company’s plans for value\ncreation and strategic positioning; market size and growth opportunities;\nregulatory conditions; competitive position; technological and market trends;\nfuture financial condition and performance; expected clinical trial results,\nincluding with respect to the RMAT-designated Allocetra™ program; market\nopportunities for the results of current clinical studies and preclinical\nexperiments; and the effectiveness of, and market opportunities for,\nAllocetra™ programs.\n\nEach forward-looking statement contained in this press release is subject to\nrisks and uncertainties that could cause actual results to differ materially\nfrom those expressed or implied by such statement. Applicable risks and\nuncertainties include, among others, the risk of failure to realize the\nanticipated benefits of the Transaction and the Company’s digital asset\ntreasury strategy; changes in business, market, financial, political, and\nregulatory conditions; risks relating to the Company’s operations and\nbusiness, including the highly volatile nature of the price, trading volume,\nand liquidity of RAIN and other cryptocurrencies; risks associated with\ndigital asset exchange listings, trading venues, and market infrastructure;\nthe risk that the price and liquidity of the Company’s ordinary shares may\nbe correlated with the price or liquidity of the digital assets it holds;\nrisks related to increased competition in the industries in which the Company\noperates; risks relating to significant legal, commercial, regulatory, and\ntechnical uncertainty regarding digital assets generally; risks relating to\nthe treatment of crypto assets for U.S. and foreign tax purposes; the risk\nthat RMAT designation does not guarantee a faster development timeline, FDA\napproval, or that all anticipated benefits of the designation will be\nrealized; and those risks and uncertainties identified in the Company’s\nfilings with the Securities and Exchange Commission. The forward-looking\nstatements in this press release speak only as of the date of this document,\nand the Company undertakes no obligation to update or revise any of these\nstatements, except as required by applicable law.\n\nENLIVEX CONTACT\n\nShachar Shlosberger, CFO\nEnlivex Ltd.\nshachar@enlivex.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/45d5c18f-a541-4d28-8298-d59d719dfea0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6KDbcy","title":"Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones","author":"Globe Newswire","ticker":"ENLV","created":"2026-07-29T12:00:00.473Z","tickers":["ENLV","1BTG"],"exchange":"NASDAQ","article_body":"Webinar to cover the rationale and value creation potential of the recently\nannounced private placement, an update on Rain protocol milestones, and recent\nclinical progress for Allocetra™, including its new RMAT designation from\nthe FDA\n\nNes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:\nENLV, “Enlivex” or “the Company”), a quality longevity company powered\nby a prediction markets treasury, today announced that its management team\nwill host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time\nto provide investors with additional detail on the Company’s recently\nannounced private placement (the “Transaction”), the status and strategy\nof its RAIN treasury, and recent clinical progress for Allocetra™.\n\nWebinar Agenda\n\nCompany management will provide an update across three areas:\n\n●     Private Placement & Treasury Strategy: the rationale for the\nTransaction, the Company’s intended use of proceeds, and how the Transaction\nfits within the Company’s long-term treasury strategy built around the Rain\nprotocol\n\n●     Rain Protocol Update: current status of the Company’s treasury\nportfolio and a review of recent milestones and the growth roadmap provided by\nthe Rain Foundation\n\n●     Clinical Update – Allocetra™: progress of the ongoing Phase 2b\ntrial in age-related knee osteoarthritis, and the recently granted\nRegenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food\nand Drug Administration (FDA) for Allocetra™ in the treatment of symptomatic\nknee osteoarthritis in patients aged 64 and older\n\nWebinar Details\n\nDate/Time: Thursday, July 30, 2026, at 10:00 AM Eastern Time\n\nRegistration: https://www.redchip.com/webinar/ENLV/82414254076\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any securities.\n\n ABOUT ENLIVEX\n\nEnlivex is a quality longevity company powered by a prediction markets\ntreasury. The Company is advancing Allocetra™, an advanced clinical-stage\nimmunotherapy targeting inflammatory conditions associated with aging, with a\nprimary focus on age-related osteoarthritis. In addition to its clinical\nprograms, Enlivex operates a prediction markets treasury strategy built around\nthe Rain protocol, the leading decentralized prediction markets infrastructure\non Arbitrum. This dual strategy combines the development of quality longevity\ntherapeutics with exposure to the emerging prediction markets ecosystem.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\nmay be identified by words such as “expects,” “plans,” “projects,”\n“will,” “may,” “anticipates,” “believes,” “should,”\n“would,” “could,” “intends,” “estimates,” “suggests,”\n“target,” “has the potential to,” “goal,” and other words of\nsimilar meaning, including statements relating to the anticipated benefits and\ntiming of the completion of the proposed Transaction and related transactions\nand the intended use of proceeds from the Transaction; the anticipated\nbenefits of the Company’s digital asset treasury strategy; the assets to be\nheld by the Company; the expected future market, price, trading activity, and\nliquidity of the RAIN token; the impact of expanded exchange listings and\nincreased token liquidity on market participation and accessibility; the\npotential effects of digital asset liquidity on the liquidity of the\nCompany’s ordinary shares; macroeconomic, political, and regulatory\nconditions surrounding digital assets; the Company’s plans for value\ncreation and strategic positioning; market size and growth opportunities;\nregulatory conditions; competitive position; technological and market trends;\nfuture financial condition and performance; expected clinical trial results,\nincluding with respect to the RMAT-designated Allocetra™ program; market\nopportunities for the results of current clinical studies and preclinical\nexperiments; and the effectiveness of, and market opportunities for,\nAllocetra™ programs.\n\nEach forward-looking statement contained in this press release is subject to\nrisks and uncertainties that could cause actual results to differ materially\nfrom those expressed or implied by such statement. Applicable risks and\nuncertainties include, among others, the risk of failure to realize the\nanticipated benefits of the Transaction and the Company’s digital asset\ntreasury strategy; changes in business, market, financial, political, and\nregulatory conditions; risks relating to the Company’s operations and\nbusiness, including the highly volatile nature of the price, trading volume,\nand liquidity of RAIN and other cryptocurrencies; risks associated with\ndigital asset exchange listings, trading venues, and market infrastructure;\nthe risk that the price and liquidity of the Company’s ordinary shares may\nbe correlated with the price or liquidity of the digital assets it holds;\nrisks related to increased competition in the industries in which the Company\noperates; risks relating to significant legal, commercial, regulatory, and\ntechnical uncertainty regarding digital assets generally; risks relating to\nthe treatment of crypto assets for U.S. and foreign tax purposes; the risk\nthat RMAT designation does not guarantee a faster development timeline, FDA\napproval, or that all anticipated benefits of the designation will be\nrealized; and those risks and uncertainties identified in the Company’s\nfilings with the Securities and Exchange Commission. The forward-looking\nstatements in this press release speak only as of the date of this document,\nand the Company undertakes no obligation to update or revise any of these\nstatements, except as required by applicable law.\n\nENLIVEX CONTACT\n\nShachar Shlosberger, CFO\nEnlivex Ltd.\nshachar@enlivex.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/45d5c18f-a541-4d28-8298-d59d719dfea0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-29T12:00:00.704339837Z","server_sent_at_ms":1785326400704},"received_at":"2026-07-29T12:00:00.809Z","source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335177/0/en/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-treasury-strategy-and-recent-clinical-milestones.html"},"analysis":{"id":"90938","press_release_id":"101914","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Enlivex announced a live webinar scheduled for July 30, 2026, to discuss its recently announced private placement and Rain protocol treasury strategy.\n\nManagement will provide updates on clinical progress for Allocetra™, including its recently granted RMAT designation from the FDA for symptomatic knee osteoarthritis.\n\nThe session will also cover the rationale for the transaction and milestones for the ongoing Phase 2b trial in patients aged 64 and older.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Webinar invitation summarizing prior clinical and capital developments; no new data released."},"keyFigures":{"drugName":"Allocetra™","phaseOfTrial":"Phase 2b"},"quotedText":"","namedEntities":{"people":[{"name":"Shachar Shlosberger","role":"CFO"}],"products":["Allocetra™","Rain protocol","RAIN token"],"companies":[{"name":"Enlivex Ltd.","ticker":"ENLV"},{"name":"Rain Foundation","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This press release serves as a webinar invitation to discuss previously disclosed events (RMAT designation, private placement). No new material financial or clinical data is published in this release."},"tickerRelevance":{"others":[],"primary":"ENLV"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"webinar_announcement"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":1,"narrative":"Enlivex announced a live webinar scheduled for July 30, 2026, to discuss its recently announced private placement and Rain protocol treasury strategy.\n\nManagement will provide updates on clinical progress for Allocetra™, including its recently granted RMAT designation from the FDA for symptomatic knee osteoarthritis.\n\nThe session will also cover the rationale for the transaction and milestones for the ongoing Phase 2b trial in patients aged 64 and older.","key_figures":{"drugName":"Allocetra™","phaseOfTrial":"Phase 2b"},"named_entities":{"people":[{"name":"Shachar Shlosberger","role":"CFO"}],"products":["Allocetra™","Rain protocol","RAIN token"],"companies":[{"name":"Enlivex Ltd.","ticker":"ENLV"},{"name":"Rain Foundation","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-29T15:16:58.992Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"webinar_announcement"}},"durationMs":466395,"modelName":"glm-4.7"}}